Co-administration With the Pharmacological Chaperone AT1001 Increases Recombinant Human α-Galactosidase A Tissue Uptake and Improves Substrate Reduction in Fabry Mice
Authors:
Open Access
- 1 April 2012
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 20 (4) , 717-726
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Agalsidase Alfa and Kidney Dysfunction in Fabry DiseaseJournal of the American Society of Nephrology, 2009
- A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry diseaseMolecular Genetics and Metabolism, 2009
- Early therapeutic intervention in females with Fabry disease?Acta Paediatrica, 2008
- Cellular and tissue localization of globotriaosylceramide in Fabry diseaseVirchows Archiv, 2007
- Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry diseaseMuscle & Nerve, 2003
- Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapyKidney International, 2002
- Natural History of Fabry Renal DiseaseMedicine, 2002
- Enzyme Replacement Therapy in Fabry DiseaseJAMA, 2001
- A Phase 1/2 Clinical Trial of Enzyme Replacement in Fabry Disease: Pharmacokinetic, Substrate Clearance, and Safety StudiesThe American Journal of Human Genetics, 2001
- Enzymatic Defect in Fabry's DiseaseNew England Journal of Medicine, 1967